Targeting mechanisms of chemotherapy resistance in breast cancer

4 Apr 2017
Monash University, Level 3 Seminar Room 15 Innovation Walk, Clayton campus

About this seminar

Treatment options for patients with triple-negative breast cancer (TNBC) are largely limited to conventional chemotherapy agents. The long-term prognosis for TNBC patients with residual disease after chemotherapy is poor. There is an urgent need to identify mechanisms that limit the efficacy of chemotherapy, and to develop combination therapy approaches to improve the treatment of TNBC. In recent years there has been renewed interest in understanding how reprogramming of cellular metabolism promotes tumour progression and therapy resistance. We have identified metabolic reprogramming events induced when TNBC cells are exposed to clinically relevant chemotherapy agents. We seek to thoroughly characterise the contribution of the identified metabolic pathways to chemotherapy resistance and identify novel therapeutic approaches to exploit these adaptive metabolic reprogramming events and sensitise TNBCs to chemotherapy. 

About the presenter

Dr Kristin Brown is a team leader in the Cancer Therapeutics Program at the Peter MacCallum Cancer Centre and holds a joint appointment in the Department of Biochemistry and Molecular Biology at the University of Melbourne. Dr Brown received her BSc and MSc degrees from the University of Canterbury (New Zealand). Following the award of her PhD from the University of Otago (New Zealand) in 2009, Dr Brown undertook post-doctoral training with Prof Alex Toker at Beth Israel Deaconess Medical Center, Harvard Medical School. In 2013, Dr Brown was promoted to Instructor in Pathology at Harvard Medical School. Dr Brown relocated to Melbourne in 2016 to establish her research laboratory investigating mechanisms that drive response or resistance to chemotherapy and targeted therapy agents in breast cancer. This knowledge is applied to the pre-clinical development of novel and more effective interventions for breast cancer therapy. 

More details

Time: 12 - 1pm

Host: Antonella Papa

Presented by: Monash Biomedicine Discovery Institute in conjunction with Monash Partners Comprehensive Cancer Consortium